Guggenheim Maintains Buy on BeOne Medicines, Raises Price Target to $430

Benzinga Newsdesk www.benzinga.com Positive 80.1%

Neg 0% Neu 0% Pos 80.1%

Guggenheim analyst Michael Schmitz maintains BeOne Medicines (NASDAQ:ONC) with a Buy and raises the price target from $420 to $430.